Nuova ricerca

CHIARA BOARINI

Personale tecnico amministrativo
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto

Home |


Pubblicazioni

2023 - Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) [Articolo su rivista]
Francesco, Salton; Paola, Confalonieri; Stefano, Centanni; Michele, Mondoni; Nicola, Petrosillo; Paolo, Bonfanti; Giuseppe, Lapadula; Donato, Lacedonia; Antonio, Voza; Nicoletta, Carpenè; Marcella, Montico; Nicolò, Reccardini; Gianfranco Umberto, Meduri; Barbara, Ruaro; Collaborative Group, Medeas; Confalonieri, Marco; Collaborative Group, Medeas; Maria Citton, Gloria; Lapadula, Giulia; Bozzi, Chiara; Tavano, Stefano; Pozzan, Riccardo; Giovanna Andrisano, Alessia; Jaber, Mohamad; Mari, Marco; Trotta, Liliana; Mondini, Lucrezia; Barbieri, Mariangela; Ruggero, Luca; Antonaglia, Caterina; Soave, Sara; Torregiani, Chiara; Bogatec, Tjaša; Baccelli, Andrea; Nalesso, Giulia; Re, Beatrice; Pavesi, Stefano; Pia Foschino Barbaro, Maria; Giuliani, Antonella; Ravaglia, Claudia; Poletti, Venerino; Scala, Raffaele; Guidelli, Luca; Golfi, Nicoletta; Vianello, Andrea; Achille, Alessia; Lucernoni, Paolo; Talia Gaccione, Anna; Romagnoli, Micaela; Fraccaro, Alessia; Malacchini, Nicola; Malerba, Mario; Sanduzzi Zamparelli, Alessandro; Bocchino, Marialuisa; Blasi, Francesco; Spotti, Maura; Miele, Carmen; Piedepalumbo, Federica; Barone, Ivan; Baglioni, Stefano; Dodaj, Meridiana; Franco, Cosimo; Andrani, Francesco; Mangia, Angelo; Mancini, Annalisa; Carrozzi, Laura; Rafanelli, Annalisa; Casto, Elisabetta; Rogliani, Paola; Ora, Josuel; Elisiana Carpagnano, Giovanna; Di Lecce, Valentina; Tamburrini, Mario; Papi, Alberto; Contoli, Marco; Luzzati, Roberto; Zatta, Marta; Di Bella, Stefano; Caraffa, Emanuela; Francisci, Daniela; Tosti, Andrea; Pallotto, Carlo; Giuseppe De Rosa, Francesco; Pecori, Alessio; Franceschini, Marta; Carlin, Massimiliano; Orsini, Valentina; Spolti, Anna; Inannace, Marta; Santantonio, Teresa; Meli, Rossella; Sauro, Sara; Fedeli, Carlo; Mangini, Elisabetta; Biolo, Gianni; Nunnari, Alessio; Pietrangelo, Antonello; Corradini, Elena; Bocchi, Davide; Boarini, Chiara; Zucchetto, Antonella; Lanini, Simone
abstract

Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.

2019 - Safety and efficacy of sucrosomal iron in inflammatory bowel disease patients with iron deficiency anemia [Articolo su rivista]
Abbati, G.; Incerti, F.; Boarini, C.; Bocchi, D.; Ventura, P.; Buzzetti, E.; Pietrangelo, A.
abstract

Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn’s Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.

2018 - Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis [Articolo su rivista]
Ascione, Antonio; De Luca, Massimo; Melazzini, Mario; Montilla, Simona; Trotta, Maria Paola; Petta, Salvatore; Puoti, Massimo; Sangiovanni, Vincenzo; Messina, Vincenzo; Bruno, Savino; Izzi, Antonio; Villa, Erica; Aghemo, Alessio; Zignego, Anna Linda; Orlandini, Alessandra; Fontanella, Luca; Gasbarrini, Antonio; Marzioni, Marco; Giannini, Edoardo G.; Craxì, Antonio; Abbati, Giuseppe; Alberti, Alfredo; Andreone, Pietro; Andreoni, Massimo; Angeli, Paolo; Angelico, Mario; Angarano, Gioacchino; Angrisani, Debora; Antinori, Andrea; Antonini, Cinzia; Avancini, Ivo; Barone, Michele; Bruno, Raffaele; Benedetti, Antonio; Bernabucci, Veronica; Blanc, Pier; Boarini, Chiara; Boffa, Nicola; Boglione, Lucio; Borghi, Vanni; Borgia, Guglielmo; Brancaccio, Giuseppina; Brunetto, Maurizia; Cacciola, Irene; Calabrese, Paolo; Calvaruso, Vincenza; Campagnolo, Davide; Canovari, Benedetta; Caporaso, Nicola; Capra, Franco; Carolo, Giada; Cassola, Giovanni; Castelli, Francesco; Cauda, Roberto; Silberstein, Francesca Ceccherini; Cecere, Roberto; Chessa, Luchino; Chiodera, Alessandro; Chirianni, Antonio; Ciancio, Alessia; Cima, Serena; Coco, Barbara; Colombo, Massimo; Coppola, Nicola; Corti, Giampaolo; Cosco, Lucio; Corradori, Silvia; Cozzolongo, Raffaele; Cristaudo, Antonio; Danieli, Elena; Monforte, Antonella D’Arminio; Monache, Marco delle; Del Poggio, Paolo; de Luca, Andrea; Dentone, Chiara; Di Biagio, Antonio; Di Leo, Alfredo; Di Perri, Giovanni; Di Stefano, Marco; D’Offizi, Giampiero; Donato, Francesca; Durante, Emanuele; Erne, Elke; Fagiuoli, Stefano; Falasca, Katia; Federico, Alessandro; Felder, Martina; Ferrari, Carlo; Gaeta, Giovanni Battista; Ganga, Roberto; Gatti, Pietro; Giacomet, Vania; Giacometti, Andrea; Gianstefani, Alice; Giordani, Maria; Giorgini, Alessia; Grieco, Antonio; Guerra, Michele; Gulminetti, Roberto; Ieluzzi, Donatella; Imparato, Michele; Iodice, Valentina; La Monica, Silvia; Lazzarin, Adriano; Lenzi, Marco; Levrero, Massimo; Lichtner, Myriam; Lionetti, Raffaella; Guercio, Carmela Lo; Madonna, Salvatore; Magnani, Silvia; Maida, Ivana; Marignani, Massimo; Marrone, Aldo; Marsetti, Fabio; Martini, Silvia; Masarone, Mario; Maserati, Renato; Mastroianni, Claudio Maria; Memoli, Massimo; Menzaghi, Barbara; Merli, Manuela; Miele, Luca; Milella, Michele; Mondelli, Mario; Montalbano, Marzia; Monti, Monica; Morelli, Olivia; Morisco, Filomena; Nardone, Gaetano; Novara, Sergio; Onnelli, Giovanna; Onofrio, Mirella; Paganin, Simona; Pani, Luca; Parisi, Maria Rita; Parruti, Giustino; Pasquazzi, Caterina; Pasulo, Luisa; Perno, Carlo Federico; Persico, Marcello; Piai, Guido; Picciotto, Antonino; Pigozzi, Grazielle Marie; Piovesan, Sara; Piras, Maria Chiara; Pirisi, Massimo; Piscaglia, Anna Maria; Ponti, Laura; Potenza, Domenico; Pravadelli, Cecilia; Quartini, Mariano; Quirino, Tiziana; Raimondo, Giovanni; Rapaccini, Gian Ludovico; Rendina, Maria; Rizzardini, Giuliano; Rizzetto, Mario; Rizzo, Salvatore; Romagnoli, Dante; Romano, Antonietta; Rossi, Cristina; Rumi, Maria Grazia; Russello, Maurizio; Russo, Francesca Paolo; Russo, Maria Luisa; Sansonno, Domenico Ettore; Santantonio, Teresa Antonia; Saracco, Giorgio; Schimizzi, Anna Maria; Serviddio, Gaetano; Simeone, Filomena; Solinas, Attilio; Soria, Alessandro; Tabone, Marco; Taliani, Gloria; Tarantino, Giuseppe; Tarquini, Pierluigi; Tavio, Marcello; Termite, Antonio; Teti, Elisabetta; Toniutto, Pierluigi; Torti, Carlo; Tundi, Paolo; Vecchiet, Giacomo; Verucchi, Gabriella; Gentilucci, Umberto Vespasiani; Vinci, Maria; Vullo, Vincenzo; Zolfino, Teresa; Zuin, Massimo
abstract

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.

2017 - Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study [Articolo su rivista]
Petta, Salvatore; Marzioni, Marco; Russo, Pierluigi; Aghemo, Alessio; Alberti, Alfredo; Ascione, Antonio; Antinori, Andrea; Bruno, Raffaele; Bruno, Savino; Chirianni, Antonio; Gaeta, Giovanni Battista; Giannini, Edoardo G; Merli, Manuela; Messina, Vincenzo; Montilla, Simona; Perno, Carlo Federico; Puoti, Massimo; Raimondo, Giovanni; Rendina, Maria; Silberstein, Francesca Ceccherini; Villa, Erica; Zignego, Anna Linda; Pani, Luca; Craxì, Antonio; Tabone, Marco; Andreoni, Massimo; Teti, Elisabetta; Angelico, Mario; Persico, Marcello; Masarone, Mario; Chiodera, Aledssandro; Solinas, Attilio; delle Monache, Marco; Cecere, Roberto; Maria Schimizzi, Anna; Piovesan, Sara; Campagnolo, Davide; Chiara Piras, Maria; Zolfino, Teresa; Paolo Russo, Francesca; Morelli, Olivia; Sangiovanni, Vincenzo; Onofrio, Mirella; Iodice, Valentina; Izzi, Antonio; Pirisi, Massimo; Danieli, Elena; Vinci, Maria; Rizzardini, Giuliano; Fagiuoli, Stefano; Pasulo, Luisa; D'Arminio Monforte, Antonella; Zuin, Massimo; Giorgini, Alessia; Simeone, Filomena; Piali, Guido; Lo Guercio, Carmela; Federico, Alessandro; Brancaccio, Giuseppina; Marrone, Aldo; Abbati, Giuseppe; Boarini, Chiara; Borghi, Vanni; Bernabucci, Veronica; Corti, Giampaolo; Monti, Monica; Rizzetto, Mario; Martini, Silvia; Andreone, Pietro; Gianstefani, Alice; Lenzi, Marco; Verucchi, Gabriella; Toniutto, Pierluigi; Borgia, Guglielmo; Caporaso, Nicola; Morisco, Filomena; Nardone, Gaetano; Angrisani, Debora; Giacometti, Andrea; Benedetti, Antonio; Tarantino, Giuseppe; Marsetti, Fabio; Tavio, Marcello; Novara, Sergio; Antonia Santantonio, Teresa; Serviddio, Gaetano; Brunetto, Maurizia; Coco, Barbara; Angarano, Gioacchino; Milella, Michele; Barone, Michele; Di Leo, Alfredo; Ettore Sansonno, Domenico; Cacciola, Irene; Boffa, Nicola; Saracco, Giorgio; Di Biagio, Antonio; Picciotto, Antonino; de Luca, Andrea; Calvaruso, Vincenza; Corradori, Silvia; Ferrari, Carlo; Orlandini, Alessandra; Maida, Ivana; Torti, Carlo; Chessa, Luchino; Felder, Martina; Vespasiani Gentilucci, Umberto; Angeli, Paolo; Romano, Antonietta; Ludovico Rapaccini, Gian; Miele, Luca; Cima, Serena; Luisa Russo, Maria; Cozzolongo, Raffaele; Onnelli, Giovanna; D'Offizi, Giampiero; Lionetti, Raffaella; Montalbano, Marzia; Guerra, Michele; Di Perri, Giovanni; Boglione, Lucio; Capra, Franco; Carolo, Giada; Ieluzzi, Donatella; Antonini, Cinzia; Termite, Antonio; Madonia, Salvatore; Tarquini, Pierluigi; Parruti, Giustino; Vecchiet, Giacomo; Falasca, Katia; Menzaghi, Barbara; Quirino, Tiziana; Dentone, Chiara; Maria Piscaglia, Anna; Rossi, Cristina; Giordani, Maria; Fontanella, Luca; Cassola, Giovanni; Russello, Maurizio; Cristaudo, Antonio; Giacomet, Vania; Colombo, Massimo; Donato, Francesca; Durante, Emanuele; Cosco, Lucio; Marignani, Massimo; Quartini, Mariano; Memoli, Massimo; Ganga, Roberto; Ponti, Laura; Soria, Alessandro; Grazia Rumi, Maria; Gulminetti, Roberto; Maserati, Renato; Mondelli, Mario; Lazzarin, Adriano; Rita Parisi, Maria; Canovari, Benedetta; Avancini, Ivo; Pravadelli, Cecilia; Blanc, Pier; Pasquazzi, Caterina; Maria Mastroianni, Claudio; Lichtner, Myriam; Distefano, Marco; Magnani, Silvia; Paganin, Simona; Erne, Elke; Gatti, Pietro; Tundi, Paolo; Calabrese, Paolo; Gasbarrini, Antonio; Grieco, Antonio; Coppola, Nicola; Del Poggio, Paolo; Levrero, Massimo; Talliani, Gloria; Vullo, Vincenzo; Cauda, Roberto; La Monica, Silvia; Potenza, Domenico; Rizzo, Salvatore; Castelli, Francesco; Marie Pigozzi, Grazielle; Ciancio, Alessia; Romagnoli, Dante; Barchetti, Federica; Ivanovic, Jelena; Longo, Olimpia; Petraglia, Sandra; Paola Trotta, Maria
abstract

Background We ran a compassionate use nationwide programme (ABACUS) to provide access to ombitasvir, paritaprevir, and ritonavir, with dasabuvir, plus ribavirin for hepatitis C virus (HCV) genotype 1 infection and ombitasvir, paritaprevir, and ritonavir, plus ribavirin for HCV genotype 4 infection in patients with cirrhosis at high risk of decompensation while approval of these regimens was pending in Italy. Methods In this prospective observational study, we collected data from a compassionate use nationwide programme from March 17, 2014, to May 28, 2015. Patients with HCV genotype 1 infection and cirrhosis at high risk of decompensation were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once daily and dasabuvir (250 mg) twice daily for 12 weeks (patients with HCV genotype 1b infection) or 24 weeks (patients with HCV genotype 1a infection). Patients with HCV genotype 4 infection were given coformulated ombitasvir (25 mg), paritaprevir (150 mg), and ritonavir (100 mg) once per day for 24 weeks. All patients were given weight-based ribavirin. The primary efficacy endpoint was sustained virological response at week 12 after the end of treatment (SVR12), analysed by intention-to-treat. Univariate and multivariate logistic regression analyses were used to identify baseline characteristics associated with SVR12. Adverse events were recorded throughout the study. Findings 728 (96%) of 762 patients with cirrhosis who were given ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin therapy for 12 or 24 weeks achieved SVR12. Logistic regression analyses identified that bilirubin concentrations of less than 2 mg/dL were associated with SVR12 (odds ratio [OR] 4·76 [95% CI 1·83–12·3]; p=0·001). 166 (23%) of 734 patients included in safety analyses had an adverse event. 25 (3%) patients discontinued treatment because of adverse events. Asthenia was the most commonly reported adverse event, occurring in 36 (5%) patients. Interpretation Our findings suggest that the safety and effectiveness of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin in patients with HCV genotype 1 or 4 infection and cirrhosis at high risk of decompensation in a real-life setting are similar to those reported in clinical trials. The concordance with clinical trials provides reassurance that the reported efficacy of this treatment in clinical trials will translate to its use in routine clinical practice. Funding Dipartimento Biomedico di Medicina Interna e Specialistica dell'Universita di Palermo.